These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36215940)

  • 1. Correlation of Vitek 2 and Agar dilution for levofloxacin susceptibility testing and clinical outcomes of Enterobacterales bacteremia with 2019 CLSI breakpoints.
    Huang HY; Chang YT; Lu PL; Yang TY; Wang YL; Chen TC; Wu JH; Lin SY
    Diagn Microbiol Infect Dis; 2022 Dec; 104(4):115799. PubMed ID: 36215940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with
    Huang HY; Wang CF; Lu PL; Tseng SP; Wang YL; Chen TC; Chang K; Tu HP; Lin SY
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019
    Humphries RM; Hindler JA; Shaffer K; Campeau SA
    J Clin Microbiol; 2019 Mar; 57(3):. PubMed ID: 30567744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four
    Karlowsky JA; Lagacé-Wiens PRS; Laing NM; Baxter MR; Adam HJ; Zhanel GG
    J Clin Microbiol; 2020 Sep; 58(10):. PubMed ID: 32817224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2015 Mar; 53(3):816-23. PubMed ID: 25540403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining VITEK
    Lellouche J; Schwartz D; Elmalech N; Ben Dalak MA; Temkin E; Paul M; Geffen Y; Yahav D; Eliakim-Raz N; Durante-Mangoni E; Iossa D; Bernardo M; Daikos GL; Skiada A; Pantazatou A; Antoniadou A; Mouton JW; Carmeli Y;
    Clin Microbiol Infect; 2019 Jun; 25(6):711-716. PubMed ID: 30291971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2017 Feb; 55(2):450-456. PubMed ID: 27881616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
    Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
    J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin Disk Diffusion Testing among Klebsiella pneumoniae Results in Frequent Inner Colonies and Categorical Disagreement Based on Conflicting Breakpoint Organization Recommendations.
    Bixby ML; Salay JM; Krueger AR; Mathers AJ; Hirsch EB
    Microbiol Spectr; 2023 Mar; 11(2):e0336322. PubMed ID: 36877020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the CLSI rAST breakpoints of Enterobacterales in positive blood cultures.
    Deng J; An Y; Kang M
    Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116335. PubMed ID: 38703531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Fosfomycin Etest To Determine
    Karlowsky JA; Baxter MR; Golden AR; Adam HJ; Walkty A; Lagacé-Wiens PRS; Zhanel GG
    J Clin Microbiol; 2021 Nov; 59(12):e0163521. PubMed ID: 34495708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
    Lazzerini G; Lavey SC; Fox BC; Munson E
    Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
    [No Abstract]   [Full Text] [Related]  

  • 14. Multicenter Evaluation of a Gradient Diffusion Method for Antimicrobial Susceptibility Testing of Helicobacter pylori.
    Shakir SM; Otiso J; Keller G; Heule HV; Osborn LJ; Cole N; Schuetz AN; Richter SS; Couturier MR
    Microbiol Spectr; 2022 Apr; 10(2):e0211121. PubMed ID: 35254119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gold standard susceptibility testing of fosfomycin in Staphylococcus aureus and Enterobacterales using a new agar dilution panel®.
    Campanile F; Wootton M; Davies L; Aprile A; Mirabile A; Pomponio S; Demetrio F; Bongiorno D; Walsh TR; Stefani S; Mezzatesta ML
    J Glob Antimicrob Resist; 2020 Dec; 23():334-337. PubMed ID: 33127523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Clinical Evaluation of Vitek 2 Meropenem-Vaborbactam for Susceptibility Testing of
    Dwivedi HP; Franklin S; Chandrasekaran S; Garner O; Traczewski MM; Beasley D; Procop GW; Tuohy M; Wilson D; Bala Y; Pincus DH
    J Clin Microbiol; 2022 Jan; 60(1):e0161021. PubMed ID: 34705536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Clinical Performance Evaluation of Omadacycline Susceptibility Testing of
    Csiki-Fejer E; Traczewski M; Procop GW; Davis TE; Hackel M; Dwivedi HP; Pincus DH
    J Clin Microbiol; 2023 Jun; 61(6):e0017423. PubMed ID: 37162363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
    J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of revised CLSI cefazolin breakpoints on the clinical outcomes of Escherichia coli bacteremia.
    Wang KC; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):768-774. PubMed ID: 26493889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of
    García-Fernández S; Bala Y; Armstrong T; García-Castillo M; Burnham CA; Wallace MA; Hardy D; Zambardi G; Cantón R
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31597745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.